JP2005151907A - 胎盤又は羊膜由来ヒト幹細胞及びその樹立方法並びに臓器への分化誘導方法 - Google Patents
胎盤又は羊膜由来ヒト幹細胞及びその樹立方法並びに臓器への分化誘導方法 Download PDFInfo
- Publication number
- JP2005151907A JP2005151907A JP2003397524A JP2003397524A JP2005151907A JP 2005151907 A JP2005151907 A JP 2005151907A JP 2003397524 A JP2003397524 A JP 2003397524A JP 2003397524 A JP2003397524 A JP 2003397524A JP 2005151907 A JP2005151907 A JP 2005151907A
- Authority
- JP
- Japan
- Prior art keywords
- human
- stem cell
- human stem
- cell
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000000130 stem cell Anatomy 0.000 title claims abstract description 107
- 210000001691 amnion Anatomy 0.000 title claims abstract description 26
- 210000002826 placenta Anatomy 0.000 title claims abstract description 25
- 238000000034 method Methods 0.000 title claims description 29
- 210000000056 organ Anatomy 0.000 title claims description 18
- 210000004027 cell Anatomy 0.000 claims abstract description 56
- 102000002260 Alkaline Phosphatase Human genes 0.000 claims abstract description 12
- 108020004774 Alkaline Phosphatase Proteins 0.000 claims abstract description 12
- 101710150336 Protein Rex Proteins 0.000 claims abstract description 12
- 230000000694 effects Effects 0.000 claims abstract description 12
- 108091023040 Transcription factor Proteins 0.000 claims abstract description 9
- 102000040945 Transcription factor Human genes 0.000 claims abstract description 9
- 230000035755 proliferation Effects 0.000 claims abstract description 7
- 210000001161 mammalian embryo Anatomy 0.000 claims description 36
- 108090000623 proteins and genes Proteins 0.000 claims description 22
- 210000001519 tissue Anatomy 0.000 claims description 20
- 238000012258 culturing Methods 0.000 claims description 11
- 102000004058 Leukemia inhibitory factor Human genes 0.000 claims description 9
- 108090000581 Leukemia inhibitory factor Proteins 0.000 claims description 9
- 210000003754 fetus Anatomy 0.000 claims description 9
- 108091003079 Bovine Serum Albumin Proteins 0.000 claims description 7
- 230000010261 cell growth Effects 0.000 claims description 5
- 210000002919 epithelial cell Anatomy 0.000 claims description 5
- 239000003102 growth factor Substances 0.000 claims description 5
- 102000009024 Epidermal Growth Factor Human genes 0.000 claims description 3
- 101800003838 Epidermal growth factor Proteins 0.000 claims description 3
- 229940116977 epidermal growth factor Drugs 0.000 claims description 3
- 238000012216 screening Methods 0.000 claims description 3
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 claims description 3
- 239000012894 fetal calf serum Substances 0.000 claims 2
- 239000002699 waste material Substances 0.000 abstract description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 10
- 108010048367 enhanced green fluorescent protein Proteins 0.000 description 10
- 101100045395 Mus musculus Tap1 gene Proteins 0.000 description 9
- 102100035423 POU domain, class 5, transcription factor 1 Human genes 0.000 description 8
- 101710126211 POU domain, class 5, transcription factor 1 Proteins 0.000 description 8
- 102000004142 Trypsin Human genes 0.000 description 7
- 108090000631 Trypsin Proteins 0.000 description 7
- 210000001035 gastrointestinal tract Anatomy 0.000 description 7
- 238000012546 transfer Methods 0.000 description 7
- 238000002054 transplantation Methods 0.000 description 7
- 239000012588 trypsin Substances 0.000 description 7
- 101100394230 Caenorhabditis elegans ham-1 gene Proteins 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- 210000000601 blood cell Anatomy 0.000 description 6
- 210000002798 bone marrow cell Anatomy 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 5
- 230000004069 differentiation Effects 0.000 description 5
- 210000002257 embryonic structure Anatomy 0.000 description 5
- 239000012091 fetal bovine serum Substances 0.000 description 5
- 239000003550 marker Substances 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 210000004748 cultured cell Anatomy 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 238000001000 micrograph Methods 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- 241000283690 Bos taurus Species 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 241000699660 Mus musculus Species 0.000 description 3
- 239000002771 cell marker Substances 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 210000003161 choroid Anatomy 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000003511 endothelial effect Effects 0.000 description 3
- 210000002219 extraembryonic membrane Anatomy 0.000 description 3
- 210000001654 germ layer Anatomy 0.000 description 3
- 210000003494 hepatocyte Anatomy 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 210000005036 nerve Anatomy 0.000 description 3
- 210000001178 neural stem cell Anatomy 0.000 description 3
- 238000011580 nude mouse model Methods 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 210000003491 skin Anatomy 0.000 description 3
- 230000009261 transgenic effect Effects 0.000 description 3
- 230000002792 vascular Effects 0.000 description 3
- 108010088751 Albumins Proteins 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 2
- 206010010356 Congenital anomaly Diseases 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 2
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 102000003745 Hepatocyte Growth Factor Human genes 0.000 description 2
- 108090000100 Hepatocyte Growth Factor Proteins 0.000 description 2
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 2
- 102100033421 Keratin, type I cytoskeletal 18 Human genes 0.000 description 2
- 108010066327 Keratin-18 Proteins 0.000 description 2
- 229930193140 Neomycin Natural products 0.000 description 2
- 102000008730 Nestin Human genes 0.000 description 2
- 108010088225 Nestin Proteins 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 2
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 2
- 102000016549 Vascular Endothelial Growth Factor Receptor-2 Human genes 0.000 description 2
- 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 description 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 2
- 210000001643 allantois Anatomy 0.000 description 2
- 210000004381 amniotic fluid Anatomy 0.000 description 2
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 210000001130 astrocyte Anatomy 0.000 description 2
- 210000002459 blastocyst Anatomy 0.000 description 2
- 210000001109 blastomere Anatomy 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 238000012790 confirmation Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 229940126864 fibroblast growth factor Drugs 0.000 description 2
- 230000002518 glial effect Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 210000003716 mesoderm Anatomy 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- 229960004927 neomycin Drugs 0.000 description 2
- 210000005055 nestin Anatomy 0.000 description 2
- 210000004498 neuroglial cell Anatomy 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 206010033675 panniculitis Diseases 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 230000010349 pulsation Effects 0.000 description 2
- 230000008929 regeneration Effects 0.000 description 2
- 238000011069 regeneration method Methods 0.000 description 2
- 210000002027 skeletal muscle Anatomy 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 210000004304 subcutaneous tissue Anatomy 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000026683 transduction Effects 0.000 description 2
- 238000010361 transduction Methods 0.000 description 2
- BRZYSWJRSDMWLG-DJWUNRQOSA-N (2r,3r,4r,5r)-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[(2s,3r,4r,5s,6r)-3-amino-4,5-dihydroxy-6-[(1r)-1-hydroxyethyl]oxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol Chemical compound O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H]([C@@H](C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-DJWUNRQOSA-N 0.000 description 1
- 101100150905 Caenorhabditis elegans ham-3 gene Proteins 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 102100028072 Fibroblast growth factor 4 Human genes 0.000 description 1
- 102100037665 Fibroblast growth factor 9 Human genes 0.000 description 1
- 101000834253 Gallus gallus Actin, cytoplasmic 1 Proteins 0.000 description 1
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 1
- 102100021519 Hemoglobin subunit beta Human genes 0.000 description 1
- 108091005904 Hemoglobin subunit beta Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101001060274 Homo sapiens Fibroblast growth factor 4 Proteins 0.000 description 1
- 101001027380 Homo sapiens Fibroblast growth factor 9 Proteins 0.000 description 1
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 1
- 101100045406 Mus musculus Tap2 gene Proteins 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 102000002584 Octamer Transcription Factor-3 Human genes 0.000 description 1
- 108010068425 Octamer Transcription Factor-3 Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102100024616 Platelet endothelial cell adhesion molecule Human genes 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000001172 blastoderm Anatomy 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 210000004413 cardiac myocyte Anatomy 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000003501 co-culture Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 210000003981 ectoderm Anatomy 0.000 description 1
- 210000001705 ectoderm cell Anatomy 0.000 description 1
- 210000001671 embryonic stem cell Anatomy 0.000 description 1
- 210000001900 endoderm Anatomy 0.000 description 1
- 210000004039 endoderm cell Anatomy 0.000 description 1
- 210000004696 endometrium Anatomy 0.000 description 1
- 210000003989 endothelium vascular Anatomy 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000002073 fluorescence micrograph Methods 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 210000000777 hematopoietic system Anatomy 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- -1 is introduced Proteins 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000008774 maternal effect Effects 0.000 description 1
- 210000001704 mesoblast Anatomy 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 230000003169 placental effect Effects 0.000 description 1
- 210000005152 placental membrane Anatomy 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 208000001608 teratocarcinoma Diseases 0.000 description 1
- 239000010409 thin film Substances 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 230000005740 tumor formation Effects 0.000 description 1
- 210000003954 umbilical cord Anatomy 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
Images
Landscapes
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2003397524A JP2005151907A (ja) | 2003-11-27 | 2003-11-27 | 胎盤又は羊膜由来ヒト幹細胞及びその樹立方法並びに臓器への分化誘導方法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2003397524A JP2005151907A (ja) | 2003-11-27 | 2003-11-27 | 胎盤又は羊膜由来ヒト幹細胞及びその樹立方法並びに臓器への分化誘導方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005151907A true JP2005151907A (ja) | 2005-06-16 |
| JP2005151907A5 JP2005151907A5 (enExample) | 2006-02-02 |
Family
ID=34722656
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003397524A Pending JP2005151907A (ja) | 2003-11-27 | 2003-11-27 | 胎盤又は羊膜由来ヒト幹細胞及びその樹立方法並びに臓器への分化誘導方法 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP2005151907A (enExample) |
Cited By (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7311905B2 (en) | 2002-02-13 | 2007-12-25 | Anthrogenesis Corporation | Embryonic-like stem cells derived from post-partum mammalian placenta, and uses and methods of treatment using said cells |
| US7311904B2 (en) | 2001-02-14 | 2007-12-25 | Anthrogenesis Corporation | Tissue matrices comprising placental stem cells, and methods of making the same |
| JP2008509699A (ja) * | 2004-08-16 | 2008-04-03 | セルリサーチ コーポレイション ピーティイー リミテッド | 臍帯羊膜からの幹／前駆細胞の単離 |
| US7468276B2 (en) | 2000-12-06 | 2008-12-23 | Anthrogenesis Corporation | Placental stem cells |
| US7682803B2 (en) | 2005-10-13 | 2010-03-23 | Anthrogenesis Corporation | Immunomodulation using placental stem cells |
| US7700090B2 (en) | 2002-02-13 | 2010-04-20 | Anthrogenesis Corporation | Co-culture of placental stem cells and stem cells from a second source |
| US7976836B2 (en) | 2000-12-06 | 2011-07-12 | Anthrogenesis Corporation | Treatment of stroke using placental stem cells |
| US8057788B2 (en) | 2000-12-06 | 2011-11-15 | Anthrogenesis Corporation | Placental stem cell populations |
| US8263065B2 (en) | 2007-09-28 | 2012-09-11 | Anthrogenesis Corporation | Tumor suppression using human placental perfusate and human placenta-derived intermediate natural killer cells |
| US8367409B2 (en) | 2008-11-19 | 2013-02-05 | Anthrogenesis Corporation | Amnion derived adherent cells |
| US8460650B2 (en) | 2007-02-12 | 2013-06-11 | Anthrogenesis Corporation | Treatment of inflammatory diseases using placental stem cells |
| US8562972B2 (en) | 2006-10-23 | 2013-10-22 | Anthrogenesis Corporation | Methods and compositions for treatment of bone defects with placental cell populations |
| US8562973B2 (en) | 2010-04-08 | 2013-10-22 | Anthrogenesis Corporation | Treatment of sarcoidosis using placental stem cells |
| US8728805B2 (en) | 2008-08-22 | 2014-05-20 | Anthrogenesis Corporation | Methods and compositions for treatment of bone defects with placental cell populations |
| WO2014132936A1 (ja) * | 2013-02-28 | 2014-09-04 | 国立大学法人 富山大学 | 胎盤・胎盤周囲組織幹細胞の選択的増幅方法 |
| US8828376B2 (en) | 2008-08-20 | 2014-09-09 | Anthrogenesis Corporation | Treatment of stroke using isolated placental cells |
| JP2014230521A (ja) * | 2013-05-29 | 2014-12-11 | 国立大学法人 東京医科歯科大学 | 細胞のリプログラミングのための組成物 |
| US8926964B2 (en) | 2010-07-13 | 2015-01-06 | Anthrogenesis Corporation | Methods of generating natural killer cells |
| US9040035B2 (en) | 2011-06-01 | 2015-05-26 | Anthrogenesis Corporation | Treatment of pain using placental stem cells |
| US9121007B2 (en) | 2010-01-26 | 2015-09-01 | Anthrogenesis Corporatin | Treatment of bone-related cancers using placental stem cells |
| US9254302B2 (en) | 2010-04-07 | 2016-02-09 | Anthrogenesis Corporation | Angiogenesis using placental stem cells |
| US9663765B2 (en) | 2009-11-12 | 2017-05-30 | Vbi Technologies, L.L.C. | Subpopulations of spore-like cells and uses thereof |
| US9763983B2 (en) | 2013-02-05 | 2017-09-19 | Anthrogenesis Corporation | Natural killer cells from placenta |
| US10104880B2 (en) | 2008-08-20 | 2018-10-23 | Celularity, Inc. | Cell composition and methods of making the same |
| JPWO2019132026A1 (ja) * | 2017-12-28 | 2021-01-14 | 株式会社カネカ | 接着性幹細胞を含む細胞集団とその製造方法、及び医薬組成物 |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7993918B2 (en) | 2006-08-04 | 2011-08-09 | Anthrogenesis Corporation | Tumor suppression using placental stem cells |
| WO2012092485A1 (en) | 2010-12-31 | 2012-07-05 | Anthrogenesis Corporation | Enhancement of placental stem cell potency using modulatory rna molecules |
-
2003
- 2003-11-27 JP JP2003397524A patent/JP2005151907A/ja active Pending
Cited By (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7976836B2 (en) | 2000-12-06 | 2011-07-12 | Anthrogenesis Corporation | Treatment of stroke using placental stem cells |
| US9149569B2 (en) | 2000-12-06 | 2015-10-06 | Anthrogenesis Corporation | Treatment of diseases or disorders using placental stem cells |
| US8580563B2 (en) | 2000-12-06 | 2013-11-12 | Anthrogenesis Corporation | Placental stem cells |
| US7468276B2 (en) | 2000-12-06 | 2008-12-23 | Anthrogenesis Corporation | Placental stem cells |
| US8545833B2 (en) | 2000-12-06 | 2013-10-01 | Anthrogenesis Corporation | Treatment of radiation injury using placental stem cells |
| US8293223B2 (en) | 2000-12-06 | 2012-10-23 | Anthrogenesis Corporation | Treatment of organ injuries and burns using placental stem cells |
| US8057788B2 (en) | 2000-12-06 | 2011-11-15 | Anthrogenesis Corporation | Placental stem cell populations |
| US8435788B2 (en) | 2001-02-14 | 2013-05-07 | Anthrogenesis Corporation | Tissue matrices comprising placental stem cells |
| US9139813B2 (en) | 2001-02-14 | 2015-09-22 | Anthrogenesis Corporation | Renovation and repopulation of decellularized tissues and cadaveric organs by stem cells |
| US7311904B2 (en) | 2001-02-14 | 2007-12-25 | Anthrogenesis Corporation | Tissue matrices comprising placental stem cells, and methods of making the same |
| US7914779B2 (en) | 2001-02-14 | 2011-03-29 | Anthrogenesis Corporation | Tissue matrices comprising placental stem cells, and methods of making the same |
| US8753883B2 (en) | 2002-02-13 | 2014-06-17 | Anthrogenesis Corporation | Treatment of psoriasis using placental stem cells |
| US8057789B2 (en) | 2002-02-13 | 2011-11-15 | Anthrogenesis Corporation | Placental stem cells derived from post-partum mammalian placenta, and uses and methods of treatment using said cells |
| US7311905B2 (en) | 2002-02-13 | 2007-12-25 | Anthrogenesis Corporation | Embryonic-like stem cells derived from post-partum mammalian placenta, and uses and methods of treatment using said cells |
| US7700090B2 (en) | 2002-02-13 | 2010-04-20 | Anthrogenesis Corporation | Co-culture of placental stem cells and stem cells from a second source |
| US10363275B2 (en) | 2004-08-16 | 2019-07-30 | Cellresearch Corporation Pte Ltd | Isolation, cultivation and uses of stem/progenitor cells |
| US9085755B2 (en) | 2004-08-16 | 2015-07-21 | Cellresearch Corporation Pte Ltd. | Isolation, cultivation and uses of stem/progenitor cells |
| US9737568B2 (en) | 2004-08-16 | 2017-08-22 | Cellresearch Corporation Pte Ltd | Isolation, cultivation and uses of stem/progenitor cells |
| JP2008509699A (ja) * | 2004-08-16 | 2008-04-03 | セルリサーチ コーポレイション ピーティイー リミテッド | 臍帯羊膜からの幹／前駆細胞の単離 |
| JP2013066473A (ja) * | 2004-08-16 | 2013-04-18 | Cellresearch Corp Pte Ltd | 臍帯羊膜からの幹／前駆細胞の単離 |
| US9539288B2 (en) | 2005-10-13 | 2017-01-10 | Anthrogenesis Corporation | Immunomodulation using placental stem cells |
| US8216566B2 (en) | 2005-10-13 | 2012-07-10 | Anthrogenesis Corporation | Treatment of multiple sclerosis using placental stem cells |
| US7682803B2 (en) | 2005-10-13 | 2010-03-23 | Anthrogenesis Corporation | Immunomodulation using placental stem cells |
| US8895256B2 (en) | 2005-10-13 | 2014-11-25 | Anthrogenesis Corporation | Immunomodulation using placental stem cells |
| US10383897B2 (en) | 2005-12-29 | 2019-08-20 | Celularity, Inc. | Placental stem cell populations |
| US8691217B2 (en) | 2005-12-29 | 2014-04-08 | Anthrogenesis Corporation | Placental stem cell populations |
| US8591883B2 (en) | 2005-12-29 | 2013-11-26 | Anthrogenesis Corporation | Placental stem cell populations |
| US9078898B2 (en) | 2005-12-29 | 2015-07-14 | Anthrogenesis Corporation | Placental stem cell populations |
| US8202703B2 (en) | 2005-12-29 | 2012-06-19 | Anthrogenesis Corporation | Placental stem cell populations |
| US8455250B2 (en) | 2005-12-29 | 2013-06-04 | Anthrogenesis Corporation | Co-culture of placental stem cells and stem cells from a second source |
| US9339520B2 (en) | 2006-10-23 | 2016-05-17 | Anthrogenesis Corporation | Methods and compositions for treatment of bone defects with placental cell populations |
| US8562972B2 (en) | 2006-10-23 | 2013-10-22 | Anthrogenesis Corporation | Methods and compositions for treatment of bone defects with placental cell populations |
| US10105399B2 (en) | 2006-10-23 | 2018-10-23 | Celularity, Inc. | Methods and compositions for treatment of bone defects with placental cell populations |
| US8916146B2 (en) | 2007-02-12 | 2014-12-23 | Anthrogenesis Corporation | Treatment of inflammatory diseases using placental stem cells |
| US8460650B2 (en) | 2007-02-12 | 2013-06-11 | Anthrogenesis Corporation | Treatment of inflammatory diseases using placental stem cells |
| US9216200B2 (en) | 2007-09-28 | 2015-12-22 | Anthrogenesis Corporation | Tumor suppression using human placental perfusate and human placenta-derived intermediate natural killer cells |
| US8263065B2 (en) | 2007-09-28 | 2012-09-11 | Anthrogenesis Corporation | Tumor suppression using human placental perfusate and human placenta-derived intermediate natural killer cells |
| US10104880B2 (en) | 2008-08-20 | 2018-10-23 | Celularity, Inc. | Cell composition and methods of making the same |
| US8828376B2 (en) | 2008-08-20 | 2014-09-09 | Anthrogenesis Corporation | Treatment of stroke using isolated placental cells |
| US8728805B2 (en) | 2008-08-22 | 2014-05-20 | Anthrogenesis Corporation | Methods and compositions for treatment of bone defects with placental cell populations |
| US8367409B2 (en) | 2008-11-19 | 2013-02-05 | Anthrogenesis Corporation | Amnion derived adherent cells |
| US9198938B2 (en) | 2008-11-19 | 2015-12-01 | Antrhogenesis Corporation | Amnion derived adherent cells |
| JP2018126171A (ja) * | 2009-11-12 | 2018-08-16 | ブイビーアイ テクノロジーズ， エルエルシー | 胞子様細胞の亜集団およびその用途 |
| US9663765B2 (en) | 2009-11-12 | 2017-05-30 | Vbi Technologies, L.L.C. | Subpopulations of spore-like cells and uses thereof |
| US9121007B2 (en) | 2010-01-26 | 2015-09-01 | Anthrogenesis Corporatin | Treatment of bone-related cancers using placental stem cells |
| US9254302B2 (en) | 2010-04-07 | 2016-02-09 | Anthrogenesis Corporation | Angiogenesis using placental stem cells |
| US8562973B2 (en) | 2010-04-08 | 2013-10-22 | Anthrogenesis Corporation | Treatment of sarcoidosis using placental stem cells |
| US8926964B2 (en) | 2010-07-13 | 2015-01-06 | Anthrogenesis Corporation | Methods of generating natural killer cells |
| US9464274B2 (en) | 2010-07-13 | 2016-10-11 | Anthrogenesis Corporation | Methods of generating natural killer cells |
| US9040035B2 (en) | 2011-06-01 | 2015-05-26 | Anthrogenesis Corporation | Treatment of pain using placental stem cells |
| US11090339B2 (en) | 2011-06-01 | 2021-08-17 | Celularity Inc. | Treatment of pain using placental stem cells |
| US9763983B2 (en) | 2013-02-05 | 2017-09-19 | Anthrogenesis Corporation | Natural killer cells from placenta |
| JPWO2014132936A1 (ja) * | 2013-02-28 | 2017-02-02 | 国立大学法人富山大学 | 胎盤・胎盤周囲組織幹細胞の選択的増幅方法 |
| WO2014132936A1 (ja) * | 2013-02-28 | 2014-09-04 | 国立大学法人 富山大学 | 胎盤・胎盤周囲組織幹細胞の選択的増幅方法 |
| JP2014230521A (ja) * | 2013-05-29 | 2014-12-11 | 国立大学法人 東京医科歯科大学 | 細胞のリプログラミングのための組成物 |
| JPWO2019132026A1 (ja) * | 2017-12-28 | 2021-01-14 | 株式会社カネカ | 接着性幹細胞を含む細胞集団とその製造方法、及び医薬組成物 |
| JP7454379B2 (ja) | 2017-12-28 | 2024-03-22 | 株式会社カネカ | 接着性幹細胞を含む細胞集団とその製造方法、及び医薬組成物 |
| JP2024063245A (ja) * | 2017-12-28 | 2024-05-10 | 株式会社カネカ | 接着性幹細胞を含む細胞集団とその製造方法、及び医薬組成物 |
| US12186345B2 (en) | 2017-12-28 | 2025-01-07 | Kaneka Corporation | Cell population including adhesive stem cells, production method therefor and pharmaceutical composition |
| JP7708909B2 (ja) | 2017-12-28 | 2025-07-15 | 株式会社カネカ | 接着性幹細胞を含む細胞集団とその製造方法、及び医薬組成物 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005151907A (ja) | 胎盤又は羊膜由来ヒト幹細胞及びその樹立方法並びに臓器への分化誘導方法 | |
| JP2005151907A5 (enExample) | ||
| JP4330995B2 (ja) | 絨毛膜絨毛、羊水、および胎盤からの胎児性幹細胞を単離、増殖、および分化させる方法、ならびにその治療的使用方法 | |
| JP4383896B2 (ja) | 脈管形成性の始原細胞をインビトロで同定し、単離し、または分化させるための新規な方法 | |
| Tamagawa et al. | Establishment and characterization of a pluripotent stem cell line derived from human amniotic membranes and initiation of germ layers in vitro | |
| KR101195838B1 (ko) | 분리된 전분화능 성체줄기세포 및 그의 분리 및 배양 방법 | |
| US8268302B2 (en) | Cultures, products and methods using umbilical cord matrix cells | |
| JP4950661B2 (ja) | 分娩後由来細胞類を使用する、神経組織の再生および修復 | |
| US20030161818A1 (en) | Cultures, products and methods using stem cells | |
| JP2022105142A (ja) | 哺乳動物種における誘導組織再生のための組成物および方法 | |
| JP2012502653A (ja) | 人工多能性幹細胞のマーカー | |
| JP2003512052A (ja) | 分化前駆細胞及び系統欠失胚性幹細胞の産生方法 | |
| US20070202596A1 (en) | Selective antibody targeting of undifferentiated stem cells | |
| CN1582331A (zh) | 衍生自灵长类胚胎干细胞的内皮细胞 | |
| JP2005520516A (ja) | 幹細胞の特定細胞系統への分化を誘発する方法 | |
| EP1414945B1 (en) | Cell culture method for obtaining prostate-like acini | |
| US20080299090A1 (en) | Use Of Umbilical Cord Matrix Cells | |
| CN109689858A (zh) | 用于产生具有体内血管形成能力的中胚层和/或内皮集落形成细胞样细胞的方法 | |
| JP4153878B2 (ja) | Ｇｔ遺伝子が除去された複製豚及びその生産方法 | |
| JP2003516141A (ja) | 長期細胞培養組成物とそれから誘導される遺伝的に修飾された動物 | |
| JP7148402B2 (ja) | インビトロで多能性幹細胞を分化誘導する方法 | |
| JP2005523685A (ja) | 体細胞由来胚幹細胞及びそれらの分化子孫 | |
| Daniel et al. | Reprogramming mouse embryonic fibroblasts with transcription factors to induce a hemogenic program | |
| JPWO2005040361A1 (ja) | 幹細胞の簡易調製法およびそれに使用するフィーダー細胞 | |
| WO2008116160A1 (en) | Use of umbilical cord matrix cells |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20051209 |